Stockscreener 앱 받기
6.35
9.48%
0.55
시장 영업 전:
6.34
-0.010
-0.16%
전일 마감가:
$5.80
열려 있는:
$5.93
하루 거래량:
4.34M
Relative Volume:
1.66
시가총액:
$1.02B
수익:
-
순이익/손실:
$-206.69M
주가수익비율:
-4.6846
EPS:
-1.3555
순현금흐름:
$-186.49M
1주 성능:
+4.96%
1개월 성능:
+12.19%
6개월 성능:
+108.88%
1년 성능:
+312.34%
1일 변동 폭
$5.91
$6.435
1주일 범위
$5.72
$6.435
52주 변동 폭
$1.40
$7.18
아넥손 Stock (ANNX) Company Profile
명칭
Annexon Inc
전화
(650) 822-5500
주소
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
6.35 | 930.75M | 0 | -206.69M | -186.49M | -1.3555 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
아넥손 Stock (ANNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-23 | 개시 | Chardan Capital Markets | Buy |
| 2024-03-01 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-10-30 | 개시 | Wells Fargo | Overweight |
| 2023-05-26 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-05-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-09-16 | 개시 | Jefferies | Buy |
| 2022-09-09 | 개시 | BTIG Research | Buy |
| 2021-11-30 | 개시 | H.C. Wainwright | Buy |
| 2021-09-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-01-26 | 개시 | Needham | Buy |
| 2020-08-18 | 개시 | BofA Securities | Buy |
| 2020-08-18 | 개시 | Cowen | Outperform |
| 2020-08-18 | 개시 | JP Morgan | Overweight |
모두보기
아넥손 주식(ANNX)의 최신 뉴스
Annexon CEO Touts “Win Year” 2026 at Needham, Eyes GA Phase III Data and GBS FDA Filing - Yahoo Finance
Annexon (NASDAQ:ANNX) Trading 8.5% Higher Following Insider Buying Activity - MarketBeat
Carson buys $49k in Annexon (ANNX) stock - Investing.com
Insider Buying: Annexon (NASDAQ:ANNX) Director Purchases 8,000 Shares of Stock - MarketBeat
Annexon (NASDAQ: ANNX) director adds 8,000 shares in planned stock purchase - Stock Titan
EV Market: Will Annexon Inc benefit from government policyWall Street Watch & Technical Buy Zone Confirmation - baoquankhu1.vn
Annexon stock rises after director purchases shares - MSN
Macro Review: Will Annexon Inc benefit from government policyPortfolio Gains Summary & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference - Bitget
Geopolitics Watch: What are the risks of holding Annexon Inc2026 Analyst Calls & Long-Term Investment Growth Plans - baoquankhu1.vn
Annexon (NASDAQ:ANNX) Shares Up 6.6%What's Next? - MarketBeat
Wall Street analysts see a 165.52% upside in Annexon (ANNX): Can the stock really move this high? - MSN
HC Wainwright Estimates Annexon FY2030 Earnings - MarketBeat
Annexon posts full-year 2025 financial results and portfolio updates - Traders Union
H.C. Wainwright Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Cyber Risks Threaten Annexon Biosciences’ Clinical Operations, Reputation and Financial Health - The Globe and Mail
Dip Buying: Can Annexon Inc reach all time highs this yearTrade Exit Report & Stepwise Trade Signal Implementation - baoquankhu1.vn
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans? - Sahm
Wall Street Analysts See a 165.52% Upside in Annexon (ANNX): Can the Stock Really Move This High? - Yahoo Finance
Multiple Insiders Sold Annexon Shares Presenting Weak Signs For Investors - 富途牛牛
Wells Fargo Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $27 - Moomoo
Big Picture: What are the risks of holding Annexon IncEarnings Growth Summary & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Jefferies reiterates Annexon Biosciences stock rating on M&A activity By Investing.com - Investing.com Canada
Annexon (ANNX) Gains Attention Amid Pharma Deal Activity - GuruFocus
Annexon (NASDAQ:ANNX) Shares Gap UpShould You Buy? - MarketBeat
Needham Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Annexon Reports Positive Q4 and Full-Year 2025 Results, Highlights Key Milestones - National Today
TD Cowen Maintains Annexon(ANNX.US) With Buy Rating - Moomoo
Annexon Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Annexon (ANNX) Advances in Neuroinflammation Treatments - GuruFocus
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones - Investing News Network
Annexon (NASDAQ:ANNX) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Annexon (NASDAQ: ANNX) advances C1q-targeted drugs for GBS and GA - Stock Titan
Annexon (NASDAQ: ANNX) widens 2025 loss but extends cash runway into 2027 - Stock Titan
Annexon Reports Fourth Quarter and Year-End 2025 Financial - GlobeNewswire
U.S. Earnings Preview: Before Market Open March 30 - Moomoo
ANNX Should I Buy - Intellectia AI
Annexon, Inc. (NASDAQ:ANNX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Vanguard disaggregates holdings; Annexon (ANNX) shows 0 shares reported - Stock Titan
Annexon (NASDAQ:ANNX) Trading Up 10.2%What's Next? - MarketBeat
Insider Sell: Will Annexon Inc be affected by tariffs2026 Retail Activity & AI Enhanced Trading Alerts - baoquankhu1.vn
Are Healthcare Stocks Falling Behind American Well (AMWL) in Performance This Year? - Bitget
Are Medical Stocks Lagging American Well (AMWL) This Year? - Yahoo Finance
U.S. Earnings Preview: Before Market Open March 23 - Moomoo
If You Invested $1,000 in Annexon, Inc. (ANNX) - Stock Titan
Analysts Offer Insights on Healthcare Companies: Annexon Biosciences (ANNX) and Electrocore (ECOR) - The Globe and Mail
ANNX PE Ratio & Valuation, Is ANNX Overvalued - Intellectia AI
Annexon, Inc. (ANNX) Discusses Vision Preservation in Geographic Atrophy With C1q Inhibition and Key Insights From ARCHER TrialsSlideshow (NASDAQ:ANNX) 2026-03-20 - Seeking Alpha
아넥손 (ANNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):